Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Status Epilepticus Clear all
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Epilepsy, Status Epilepticus, Epilepsia Partialis Continua, Epilepsia Partialis Continua, Refractory (Medically)
Interventions
Low frequency repeated TMS (LF-rTMS)
Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced May 21, 2026, 7:38 PM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced May 21, 2026, 7:38 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Status Epilepticus
Interventions
propofol, thiopental/pentobarbital
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced May 21, 2026, 7:38 PM EDT
Not yet recruiting Phase 4 Interventional
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 7:38 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced May 21, 2026, 7:38 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions
Vatiquinone, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 20 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 21, 2026, 7:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Super-refractory Status Epilepticus
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced May 21, 2026, 7:38 PM EDT
Not yet recruiting Phase 3 Interventional
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Super-Refractory Status Epilepticus
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
100
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 21, 2026, 7:38 PM EDT
Terminated Phase 4 Interventional
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 21, 2026, 7:38 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Status Epilepticus, Refractory Status Epilepticus
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced May 21, 2026, 7:38 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
Traditional Treatment (Group T), Ketamine Infusion (Group K)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced May 21, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Benzodiazepine Refractory Status Epilepticus
Interventions
Fosphenytoin, Levetiracetam, Valproic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
2 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
65
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced May 21, 2026, 7:38 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hypoxia-Ischemia, Brain, Heart Arrest, Status Epilepticus, Refractory Status Epilepticus, Seizures, Anoxic-Ischemic Encephalopathy, Anoxia-Ischemia, Cerebral
Interventions
Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced May 21, 2026, 7:38 PM EDT